Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro susceptibility of varicella zoster virus to adenine arabinoside and hypoxanthine arabinoside.

Literature DB >> 176937

In vitro susceptibility of varicella zoster virus to adenine arabinoside and hypoxanthine arabinoside.

Abstract

The in vitro susceptibility of varicella zoster (VZ) isolates to adenine arabinoside (ara-A) and hypoxanthine arabinoside (ara-Hx) was determined in human skin fibroblasts. Using a system in which deamination was inhibited, and using a modified plaque reduction method, the antiviral activities of ara-A and ara-Hx were separated. The plaque inhibitory concentration of ara-A for all VZ isolates tested was 1 to 2 mug/ml and 80 to 100 mug/ml for ara-Hx. A comparison of antiviral activity based upon total plaque suppression gave a rate of 40 to 50:1, in favor of ara-A.

Entities: Chemical Species

Mesh：

Substances：

Year: 1976 PMID： 176937 PMCID： PMC429566 DOI： 10.1128/AAC.9.3.540

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

1. A NEW MEMBER OF THE HERPESVIRUS GROUP ISOLATED FROM SOUTH AMERICAN MARMOSETS.

Authors: J L MELNICK; M MIDULLA; I WIMBERLY; J G BARRERA-ORO; B M LEVY
Journal: J Immunol Date: 1964-04 Impact factor: 5.422

2. Plaque assay for measurement of cells infected with zoster virus.

Authors: F RAPP; M BENYESH-MELNICK
Journal: Science Date: 1963-08-02 Impact factor: 47.728

3. INHIBITION OF VARICELLA VIRUS BY 5-IODO-2'-DEOXYURIDINE.

Authors: W E RAWLS; R A COHEN; E C HERRMANN
Journal: Proc Soc Exp Biol Med Date: 1964-01

4. Serial propagation in vitro of agents producing inclusion bodies derived from varicella and herpes zoster.

Authors: T H WELLER
Journal: Proc Soc Exp Biol Med Date: 1953-06

5. Treatment of varicella-zoster virus infections with adenine arabinoside.

Authors: M T Johnson; R A Buchanan; J P Luby; D Mikulec
Journal: J Infect Dis Date: 1975-03 Impact factor: 5.226

6. Susceptibility of herpesviruses to three nucleoside analogues and their combinations and enhancement of the antiviral effect of acid pH.

Authors: M Fiala; A W Chow; K Miyasaki; L B Guze
Journal: J Infect Dis Date: 1974-01 Impact factor: 5.226

7. Observations on the growth of varicella-zoster virus in human diploid cells.

Authors: A Gershon; L Cosio; P A Brunell
Journal: J Gen Virol Date: 1973-01 Impact factor: 3.891

8. Effect of adenosine deaminase upon the antiviral activity in vitro of adenine arabinoside for vaccinia virus.

Authors: J D Connor; L Sweetman; S Carey; M A Stuckey; R Buchanan
Journal: Antimicrob Agents Chemother Date: 1974-11 Impact factor: 5.191

9. The antiviral activity of 9-beta-D-arabinofuranosyladenine (ARA-A).

Authors: F M Schabel
Journal: Chemotherapia (Basel) Date: 1968

10. The etiologic agents of varicella and herpes zoster; isolation, propagation, and cultural characteristics in vitro.

Authors: T H WELLER; H M WITTON; E J BELL
Journal: J Exp Med Date: 1958-12-01 Impact factor: 14.307

10 in total

11 in total

1. Characterization of an Epstein-Barr virus-induced DNA polymerase.

Authors: T Ooka; G Lenoir; J Daillie
Journal: J Virol Date: 1979-01 Impact factor: 5.103

2. Synthesis and biological evaluation of some phosphate triester derivatives of the anti-viral drug AraA.

Authors: C McGuigan; S M Tollerfield; P A Riley
Journal: Nucleic Acids Res Date: 1989-08-11 Impact factor: 16.971

3. Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis.

Authors: J F Gephart; A M Lerner
Journal: Antimicrob Agents Chemother Date: 1981-01 Impact factor: 5.191

4. In vitro susceptibility of varicella-zoster virus to acyclovir.

Authors: K K Biron; G B Elion
Journal: Antimicrob Agents Chemother Date: 1980-09 Impact factor: 5.191

5. Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds.

Authors: S R Preblud; A M Arbeter; E A Proctor; S E Starr; S A Plotkin
Journal: Antimicrob Agents Chemother Date: 1984-04 Impact factor: 5.191

6. Effect of 5-iodo-5'-amino-2',5'-dideoxyuridine on varicella-zoster virus in vitro.

Authors: J P Iltis; T S Lin; W H Prusoff; F Rapp
Journal: Antimicrob Agents Chemother Date: 1979-07 Impact factor: 5.191

7. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

Authors: E De Clercq; J Descamps; M Ogata; S Shigeta
Journal: Antimicrob Agents Chemother Date: 1982-01 Impact factor: 5.191

8. Antiviral activity of arabinosyladenine and arabinosylhypoxanthine in herpes simplex virus-infected KB cells: selective inhibition of viral deoxyribonucleic acid synthesis in the presence of an adenosine deaminase inhibitor.

Authors: P M Schwartz; C Shipman; J C Drach
Journal: Antimicrob Agents Chemother Date: 1976-07 Impact factor: 5.191

9. Antiviral and antimetabolic activities of neplanocins.

Authors: E De Clercq
Journal: Antimicrob Agents Chemother Date: 1985-07 Impact factor: 5.191

10. Combined antiviral effects of interferon, adenine, arabinoside, hypoxanthine arabinoside, and adenine arabinoside-5'-monophosphate in human fibroblast cultures.

Authors: Y J Bryson; L H Kronenberg
Journal: Antimicrob Agents Chemother Date: 1977-02 Impact factor: 5.191